CollPlant (CLGN) Receives New EU Patent

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively.

This newly allowed patent application pertains to CollPlant's injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. The European Patent Application is directed, among other things, to a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler within it, each based on its recombinant human collagen (rhCollagen).

Yehiel Tal, CollPlant's Chief Executive Officer, commented, "This patent, effective until 2041, represents an integral part of the Company's strategy to expand the uses for its novel, rhCollagen technology into new, high-value markets. The market for injectable soft-tissue fillers is significant and growing, currently estimated to be over $6 billion, and the addressable market for breast implants, either for cosmetic or reconstructive surgery, is also significant, estimated at over $3 billion, so we are very keen on preparing and maintaining market leadership in these areas. We have been steadily building our protection around our proprietary technology – from composition to use and application - and this clearly strengthens the competitiveness of our programs. Europe is one of CollPlant's strategic target markets, and we see the strengthening of our intellectual property in this territory as a significant achievement."

About CollPlant's Photocurable Dermal Filler

CollPlant is developing an rhCollagen-based photocurable regenerative dermal and soft filler comprised of rhCollagen and other substances which is intended to provide several revolutionary effects: lifting, sculpturing ability, retention to the host tissue, and tissue regeneration.

The photocurable regenerative filler is intended for injection in a semiliquid phase and hardened in-situ post injection by light illumination through the skin. Utilization of photocuring technology is expected to ease the injection process, particularly in subcutaneous and supraperiosteal applications.

As the product degrades, a newly formed tissue is expected to regenerate and take its place. The soft tissue fillers market is estimated at $6.3 billion annually with a 10% growth rate.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Active options: TSLA NVDA SPCX MU AAPL AMD INTC AMZN
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027